Rodman & Renshaw Terminates Coverage of Biostar Pharmaceuticals

Loading...
Loading...
Rodman & Renshaw terminated its coverage of Biostar Pharmaceuticals
BSPM
. The rating agency's last rating on the company's stock was Market Outperform with a price target of 7. On Friday, BSPM added 5.22% to its value to finish the week at $1.41.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsRodman and Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...